New Delhi: In its boldest transfer but, Solar Pharma, India’s largest pharma firm, has struck the biggest-ever abroad pharma deal, buying US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction.The deal broadens Solar Pharma’s therapeutic breadth and geographic attain in a single sweep, including over 140 high-growth markets together with China, and a portfolio round revolutionary therapies, together with girls’s well being, biosimilars, and legacy manufacturers.Solar Pharma pays $14 per share, a premium of over 24% to Organon’s final closing value on April 24 in one of many largest M&A offers by an Indian firm. On Monday, Solar Pharma shares closed 7% greater at Rs 1,734 on BSE.

Indian firm now third largest in girls’s well being

As soon as accomplished, the acquisition will double Solar Pharma’s income to $12.4 billion and its EBITDA to $3.7 billion, rating it among the many high 25 international pharmaceutical corporations.Organon, spun off in 2021 from Merck (often known as MSD outdoors US and Canada), brings portfolio of over 70 merchandise throughout girls’s well being, basic medicines and biosimilars, together with six manufacturing amenities worldwide.The deal follows Solar Pharma’s confirmed M&A playbook from the landmark Ranbaxy acquisition in 2014 to a string of in-licensing offers, which have strengthened its revolutionary portfolio and delivered a 14% income CAGR between FY10 and FY25.Solar chairman Dilip Shanghvi stated: “We’re debt-averse, however we’re by no means risk-averse. Biosimilars is a phase the place constructing capabilities organically would take years; Organon provides us that platform instantly.”The deal positions Solar Pharma as the highest 3 participant in girls’s well being, after German corporations Merck and Bayer, and the seventh-largest biosimilars firm on the planet — two of the fastest-growing segments. “Solar Pharma’s proposed take care of Organon, valued round 6x EBITDA, seems financially disciplined, supported by regular money flows,” Vishal Manchanda analyst at Systematix stated.